15994 results about "Isopropylene glycol" patented technology

The present invention provides a dissolvable medical sealing device (3, 4; 6, 7; 9) for closing a wound in vessel. A sealing device (3, 4, 6, 7, 9) according to the invention is made of a material that dissolves by means of physical processes, rather than by means of chemical or biological processes. Such a sealing device (3, 4; 6, 7; 9) can be made of polyethylene glycol, polypropylene glycol, copolymers containing ethylene glycol and propylene glycol, polyvinyl alcohol or polyvinyl pyrolidone, or any combinations thereof.

A lyophilization process which comprises dissolving a material in one or more solvents for said material to form a solution; forcing said material at least partially out of solution by combining the solution and a non-solvent for the material, which non-solvent is miscible with the solvent or solvents used and wherein said non-solvent is volatilizable under freeze-drying conditions. In addition, for hydrophobic and / or lipophilic materials, the anti-solvent can be omitted, and the solution of the material in the solvent can be subjected directly to freeze drying. The lyophilizates can then be reconstituted with typical aqueous diluent in the case of hydrophilic materials. Hydrophobic and or lipophilic materials can be initially reconstituted with propylene glycol and / or polyethyleneglycol to form a high concentration solution therein and this is further diluted for use with a diluent of Intralipid, plasma, serum, or even whole blood.

The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition.

The invention is a continuous process for the preparation of polytrimethylene ether glycol from 1,3-propanediol reactant. In addition, the invention is directed to a continuous multi-stage process comprising reacting at least one reactant in a liquid phase in an up-flow column reactor, and forming a gas or vapor phase by-product wherein the gas or vapor phase by-product is continuously removed at the top and at least one intermediate stage.

Methods for hydrogenolysis are described which use a Re-containing multimetallic catalyst for hydrogenolysis of both C—O and C—C bonds. Methods and compositions for reactions of hydrogen over a Re-containing catalyst with compositions containing a 6-carbon sugar, sugar alcohol, or glycerol are described. It has been surprisingly discovered that reaction with hydrogen over a Re-containing multimetallic catalyst resulted in superior conversion and selectivity to desired products such as propylene glycol.

A process for the manufacture of polytrimethylene ether glycol comprising the steps of: (a) providing (1) 1,3-propanediol reactant selected from the group consisting of 1,3-propanediol and / or oligomers or prepolymers of 1,3-propanediol having a degree of polymerization of 2-9 and mixtures thereof, and (2) a polycondensation catalyst; and (b) polycondensing the 1,3-propanediol reactant to form a polytrimethylene ether glycol at less than one atmosphere pressure, and the product of the process. In addition, polytrimethylene ether glycol has a number average molecular weight greater than 1,500, an APHA color of less than 120, an unsaturation of less than 20 meq / kg, and a content of cyclic ether oligomers of less than 2%.

Disclosed is a process for the removal of impurities, especially color forming impurities, from 1,3-propanediol.

A pharmaceutical composition for topical administration, including, as the pharmaceutically active component, at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent composition including at least two of water, a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.

Composition for pharmaceutical or cosmetic use, capable of forming a microemulsion, comprising at least: an active principle, a lipophilic phase consisting of a mixture of fatty acid esters and glycerides, a surfactant (SA), a cosurfactant (CoSA), a hydrophilic phase, characterized: in that the lipophilic phase consists of a mixture of C8 to C18 polyglycolized glycerides having a hydrophilic-lipophilic balance (HLB) of less than 16, this lipophilic phase representing from 30 to 75% of the total weight of the composition; in that the surfactant (SA) is chosen from the group comprising saturated C8-C10 olyglycolized glycerides and oleic esters of polyglycerol, this surfactant having an HLB of less than 16; in that the cosurfactant (CoSA) is chosen from the group comprising lauric esters of propylene glycol, oleic esters of polyglycerol and ethyl diglycol; in that the SA / CoSA ratio is between 0.5 and 6; and in that the hydrophilic phase of the final microemulsion is supplied after ingestion by the physiological fluid of the digestive milieu.

A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. At least one of the anode and the cathode includes an electrode and a reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes (i) a drug or an electrolyte salt or a mixture thereof, (ii) propylene glycol, and (iii) an antimicrobial agent in an amount sufficient to inhibit microbial growth in the aqueous medium. The propylene glycol prevents the antimicrobial agent from being adsorbed by other materials used in the construction of the delivery device. A process for preparing a transdermal electrotransport drug delivery device is also provided.

The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition.

A reactive-separation process converts glycerin into lower alcohols, having boiling points less than 200° C., at high yields. Conversion of natural glycerin to propylene glycol through an acetol intermediate is achieved at temperatures from 150° to 250° C. at a pressure ranging from 1 and 25 bar. The preferred applications of the propylene glycol are as an antifreeze, deicing compound, or anti-icing compound. The preferred catalyst for this process in a copper-chromium powder.

A process for the manufacture of polytrimethylene ether glycol comprising the steps of: (a) providing (1) 1,3-propanediol reactant selected from the group consisting of 1,3-propanediol and / or oligomers or prepolymers of 1,3-propanediol having a degree of polymerization of 2-9 and mixtures thereof, and (2) a polycondensation catalyst; and (b) polycondensing the 1,3-propanediol reactant to form a polytrimethylene ether glycol at less than one atmosphere pressure, and the product of the process. In addition, polytrimethylene ether glycol has a number average molecular weight greater than 1,500, an APHA color of less than 120, an unsaturation of less than 20 meq / kg, and a content of cyclic ether oligomers of less than 2%.

The invention relates to a continuous reaction process flow for producing ethylene glycol and 1, 2-propylene glycol through continuous hydrocrackin of sugars and provides a method for producing the ethylene glycol and the 1,2-propylene glycol through continuous hydrocrackin of sugars. In the process flow, sugars (comprising one or more than two of sugar, glucose, fructose, xylose, soluble xylo-oligosaccharide and starch) are hydrocracked in the presence of a catalyst in a reactor and the hydrocracked product enters a separating system. Hydrogen gas in a gas phase is recycled by separating and recovering; a liquid phase product partially reflows to the reactor and other liquid phase products are refined and separated to form the ethylene glycol, the propylene glycol and other polyhydric alcohols; and concentrated soluble catalyst components in the refined and separated residual component liquid phase are partially returned to the reactor.

An aqueous cutting fluid which can reduce the impact on working environment and the global environment, and can achieve both preventing precipitates from becoming a hard cake and keeping high dispersibility for abrasive grains is provided. Such an aqueous cutting fluid is obtained by a method comprising dispersing abrasive grains (G) in an aqueous composition comprising a dispersion medium (M) containing a hydrophilic alcohol compound such as ethylene glycol, a lipophilic alcohol compound such as propylene glycol and water, and silica colloid particles dispersed stably in the medium. The dispersion medium (M) is odorless and not flammable. The abrasive grains (G) may settle out after a time, but they do not closely contact with one another, and therefore the resulting precipitates do not become a hard cake, which allows the re-dispersion and reuse of precipitated grains. The instant aqueous cutting fluid is inherently low viscous, and the reduction of viscosity owing to the contamination of water and the increase of viscosity owing to contamination of shavings are both moderate. As a result, the cutting fluid has a long life. And articles which have been cut using the cutting fluid can be washed with water. Further, as the dispersion medium (M) is a biodegradable low molecular weight organic compound, a waste liquid from a process using the cutting fluid can be disposed with an activated sludge.

The invention is a continuous process for the preparation of polytrimethylene ether glycol from 1,3-propanediol reactant. In addition, the invention is directed to a continuous multi-stage process comprising reacting at least one reactant in a liquid phase in an up-flow column reactor, and forming a gas or vapor phase by-product wherein the gas or vapor phase by-product is continuously removed at the top and at least one intermediate stage.

Topical aqueous suspension compositions of sparingly soluble ophthalmic drugs are disclosed. The compositions comprise a combination of a poloxamer or meroxapol surfactant and a glycol tonicity-adjusting agent such as propylene glycol.

Dental bleaching compositions that include sucralose. The bleaching agent is dispersed within a carrier, which is optimally sticky and viscous such as a mixture of propylene glycol and silica fume. Anhydrous propylene glycol and / or anhydrous glycerin are especially useful in order to maintain the desired degree of hydration of the perborate being used. Flavorants may be added to enhance the taste of the dental compositions, since they will be used within a person's mouth. For best results, a flexible, thin-walled, comfortable-fitting, custom dental tray is used with the dental bleaching compositions. The dental compositions are sufficiently sticky and viscous so as to adhere and retain a dental tray against a person's teeth which is designed so as to not exert significant mechanical pressure onto the person's teeth.

Dental bleaching compositions that include sucralose as a non-nutritive sweetener. The bleaching agent is dispersed within a carrier, which is optimally sticky and viscous, such as a mixture of a liquid or solvent carrier and a tackifying agent. Propylene glycol and / or glycerin are especially useful liquid or solvent carriers. Flavorants may be added to enhance the taste of the dental compositions, since they will be used within a person's mouth. For best results, a flexible, thin-walled, comfortable-fitting, custom dental tray is used with the dental bleaching compositions. The dental compositions are preferably sufficiently sticky and viscous so as to adhere and retain a dental tray against a person's teeth which is designed so as to not exert significant mechanical pressure onto the person's teeth.

Methods and compositions for reactions of hydrogen over a Re-containing catalyst with compositions containing a 5-carbon sugar, sugar alcohol, or lactic acid are described. It has been surprisingly discovered that reaction with hydrogen over a Re-containing multimetallic catalyst resulted in superior conversion and selectivity to desired products such as propylene glycol. A process for the synthesis of PG from lactate or lactic acid is also described.

The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides.

The present invention provides an improved process for the hydrogenation of 3-hydroxypropanal to 1,3-propanediol which comprises purifying an aqueous solution of 3-hydroxypropanal by contacting said aqueous solution with a purifying agent prior to hydrogenation.

The invention discloses light-fragrance electronic cigarette atomized smoke solution and a preparation method thereof. The atomized smoke solution comprises the following components in percentage by weight: 30-45 percent of propylene glycol, 20-35 percent of glycerol, 5-15 percent of deionized water, 5-15 percent of alcohol, 15-45 percent of traditional Chinese medicine liquid, 2-5 percent of tobacco flavor, 2-6 percent of tobacco extract and 0.1-2 percent of forming agent, wherein the traditional Chinese medicine liquid is extraction liquid which is obtained by extracting traditional Chinese medicine mixture through water distillation or alcohol extraction, and the traditional Chinese medicine mixture consists of tendrilleaf fritillary bulb, mint leaf, loquat leaf, dendranthema indicum, violet, sweet-scented osmanthus and green tea. The light-fragrance electronic cigarette atomized smoke solution not only can meet the smoking demands of smokers, but also can effectively reduce irritation of smoke to tracheas, bronchi, throats and lungs of bodies, and has the efficacies of clearing heat, moistening lungs, arresting coughs, expelling phlegm, refreshing and restoring consciousness, regulating qi-flowing, resolving stagnation and the like.

A chewing gum including non-crystalline sorbitol and method of making the same is provided. The chewing gum composition comprises a sugarless syrup made from aqueous sorbitol, a plasticizing agent selected from the group consisting of glycerin, propylene glycol and mixtures thereof, and a hydrogenated starch hydrolyzate syrup. Other confectionaries can be made from the same sugarless syrup.

Pharmaceutical formulations, kits and vessels are provided for delivering decitabine to a patient suffering from a disease in need of treatment with decitabine. The pharmaceutical formulation comprises decitabine solvated in a non-aqueous solvent that comprises glycerin, propylene glycol, polyethylene glycol, or combinations. Such formulations are more chemically stable than conventional liquid formulations of decitabine containing more than 40% water in volume. The pharmaceutical formulations can be used for any disease that is sensitive to the treatment with decitabine, such as hematological disorders and cancer.

The present invention provides processes for the manufacturing of polypeptide conjugates. In particular, the invention provides methods for the purification of polypeptide conjugates, which include at least one polymeric modifying groups, such as a poly(alkylene oxide) moiety. Exemplary poly(alkylene oxide) moieties include poly(ethylene glycol) (PEG) and poly(propylene glycol). In an exemplary process, hydrophobic interaction chromatography (HIC) is used to resolve different glycoforms of glycoPEGylated polypeptides.